tiprankstipranks
Arcus Biosciences (RCUS)
NYSE:RCUS
US Market
RCUS
Arcus Biosciences
RESEARCH TOOLSreports
Want to see RCUS full AI Analyst Report?

Arcus Biosciences (RCUS) Stock Forecast & Price Target

547 Followers
See the Price Targets and Ratings of:

RCUS Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Arcus
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RCUS Stock 12 Month Forecast

Average Price Target

$38.44
▲(35.27% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $38.44 with a high forecast of $47.00 and a low forecast of $23.00. The average price target represents a 35.27% change from the last price of $28.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","18":"$18","28":"$28","38":"$38","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.44444444444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18,28,38,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.19,29.63692307692308,31.083846153846153,32.53076923076923,33.97769230769231,35.424615384615386,36.871538461538464,38.318461538461534,39.76538461538462,41.21230769230769,42.65923076923077,44.106153846153845,45.55307692307692,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.19,28.97880341880342,29.767606837606838,30.556410256410256,31.345213675213675,32.134017094017096,32.922820512820515,33.71162393162393,34.50042735042735,35.28923076923077,36.07803418803419,36.866837606837606,37.655641025641025,{"y":38.44444444444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.19,27.790769230769232,27.391538461538463,26.992307692307694,26.593076923076925,26.193846153846156,25.794615384615383,25.395384615384614,24.996153846153845,24.596923076923076,24.197692307692307,23.798461538461538,23.39923076923077,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.92,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.19,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$47.00Average Price Target$38.44Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on RCUS
Jason Zemansky
Bank of America Securities
Bank of America Securities
$29
Hold
2.04%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (NYSE: HLN), Arcus Biosciences (NYSE: RCUS) and Solventum Corporation (NYSE: SOLV)
Morgan Stanley Analyst forecast on RCUS
Terence Flynn
Morgan Stanley
Morgan Stanley
$22→$23
Hold
-19.07%
Downside
Assigned
08/10/26
Morgan Stanley Keeps Their Hold Rating on Arcus Biosciences (RCUS)
Goldman Sachs Analyst forecast on RCUS
Richard Law CFA
Goldman Sachs
Goldman Sachs
$34→$42
Buy
47.78%
Upside
Assigned
08/10/26
Arcus Biosciences price target raised to $42 from $34 at Goldman SachsArcus Biosciences price target raised to $42 from $34 at Goldman Sachs
Wells Fargo Analyst forecast on RCUS
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$23→$26
Hold
-8.52%
Downside
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), Kymera Therapeutics (NASDAQ: KYMR) and Rigel (NASDAQ: RIGL)
Wedbush Analyst forecast on RCUS
Robert Driscoll
Wedbush
Wedbush
$41→$43
Buy
51.30%
Upside
Reiterated
08/06/26
Wedbush Remains a Buy on Arcus Biosciences (RCUS)
H.C. Wainwright Analyst forecast on RCUS
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$45
Buy
58.34%
Upside
Reiterated
08/06/26
Arcus Biosciences: Broad Casdatifan Strategy in ccRCC Supports Buy Rating with Unchanged $45 Price Target
Truist Financial Analyst forecast on RCUS
Supawat Thongthip
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Revolution Medicines (NASDAQ: RVMD)
LifeSci Capital Analyst forecast on RCUS
Charles Zhu
LifeSci Capital
LifeSci Capital
$46
Buy
61.86%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
Mizuho Securities Analyst forecast on RCUS
Salim Syed
Mizuho Securities
Mizuho Securities
$47
Buy
65.38%
Upside
Reiterated
08/05/26
Salim Syed Initiates Buy on Arcus, Citing Casdatifan’s Foundational RCC Potential and Diversified Late-Stage Pipeline Ahead of 2026 Inflection Data
Citi Analyst forecast on RCUS
Yigal Nochomovitz
Citi
Citi
$45
Buy
58.34%
Upside
Reiterated
07/22/26
Buy Rating Reaffirmed on Arcus Biosciences as New RCC Partnerships Strengthen Multi-Line Development Strategy
Leerink Partners Analyst forecast on RCUS
Daina Graybosch
Leerink Partners
Leerink Partners
$49→$47
Buy
65.38%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (NASDAQ: TCRX) and Arcus Biosciences (NYSE: RCUS)
Evercore ISI Analyst forecast on RCUS
Jonathan Miller
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
03/02/26
Evercore ISI Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
Barclays Analyst forecast on RCUS
Peter Lawson
Barclays
Barclays
$14
Buy
-50.74%
Downside
Reiterated
10/28/25
Arcus Biosciences (RCUS) Receives a Buy from Barclays
Cantor Fitzgerald Analyst forecast on RCUS
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/08/25
Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on RCUS
Jason Zemansky
Bank of America Securities
Bank of America Securities
$29
Hold
2.04%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (NYSE: HLN), Arcus Biosciences (NYSE: RCUS) and Solventum Corporation (NYSE: SOLV)
Morgan Stanley Analyst forecast on RCUS
Terence Flynn
Morgan Stanley
Morgan Stanley
$22→$23
Hold
-19.07%
Downside
Assigned
08/10/26
Morgan Stanley Keeps Their Hold Rating on Arcus Biosciences (RCUS)
Goldman Sachs Analyst forecast on RCUS
Richard Law CFA
Goldman Sachs
Goldman Sachs
$34→$42
Buy
47.78%
Upside
Assigned
08/10/26
Arcus Biosciences price target raised to $42 from $34 at Goldman SachsArcus Biosciences price target raised to $42 from $34 at Goldman Sachs
Wells Fargo Analyst forecast on RCUS
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$23→$26
Hold
-8.52%
Downside
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), Kymera Therapeutics (NASDAQ: KYMR) and Rigel (NASDAQ: RIGL)
Wedbush Analyst forecast on RCUS
Robert Driscoll
Wedbush
Wedbush
$41→$43
Buy
51.30%
Upside
Reiterated
08/06/26
Wedbush Remains a Buy on Arcus Biosciences (RCUS)
H.C. Wainwright Analyst forecast on RCUS
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$45
Buy
58.34%
Upside
Reiterated
08/06/26
Arcus Biosciences: Broad Casdatifan Strategy in ccRCC Supports Buy Rating with Unchanged $45 Price Target
Truist Financial Analyst forecast on RCUS
Supawat Thongthip
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Revolution Medicines (NASDAQ: RVMD)
LifeSci Capital Analyst forecast on RCUS
Charles Zhu
LifeSci Capital
LifeSci Capital
$46
Buy
61.86%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
Mizuho Securities Analyst forecast on RCUS
Salim Syed
Mizuho Securities
Mizuho Securities
$47
Buy
65.38%
Upside
Reiterated
08/05/26
Salim Syed Initiates Buy on Arcus, Citing Casdatifan’s Foundational RCC Potential and Diversified Late-Stage Pipeline Ahead of 2026 Inflection Data
Citi Analyst forecast on RCUS
Yigal Nochomovitz
Citi
Citi
$45
Buy
58.34%
Upside
Reiterated
07/22/26
Buy Rating Reaffirmed on Arcus Biosciences as New RCC Partnerships Strengthen Multi-Line Development Strategy
Leerink Partners Analyst forecast on RCUS
Daina Graybosch
Leerink Partners
Leerink Partners
$49→$47
Buy
65.38%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (NASDAQ: TCRX) and Arcus Biosciences (NYSE: RCUS)
Evercore ISI Analyst forecast on RCUS
Jonathan Miller
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
03/02/26
Evercore ISI Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
Barclays Analyst forecast on RCUS
Peter Lawson
Barclays
Barclays
$14
Buy
-50.74%
Downside
Reiterated
10/28/25
Arcus Biosciences (RCUS) Receives a Buy from Barclays
Cantor Fitzgerald Analyst forecast on RCUS
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/08/25
Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcus Biosciences

3 Months
Emily BodnarH.C. Wainwright
Success Rate
13/14 ratings generated profit
93%
Average Return
+25.46%
Copying Emily Bodnar's trades and holding each position for 3 Months would result in 92.86% of your transactions generating a profit, with an average return of +25.46% per trade.
1 Year
Emily BodnarH.C. Wainwright
Success Rate
14/14 ratings generated profit
100%
Average Return
+74.78%
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.78% per trade.
2 Years
Emily BodnarH.C. Wainwright
Success Rate
14/14 ratings generated profit
100%
Average Return
+88.29%
Copying Emily Bodnar's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +88.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCUS Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
11
7
5
6
10
Buy
5
7
7
7
6
Hold
3
2
2
1
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
16
14
14
20
In the current month, RCUS has received 16 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the past 3 months is 38.44.
Each month's total comprises the sum of three months' worth of ratings.

RCUS Financial Forecast

RCUS Earnings Forecast

Next quarter’s earnings estimate for RCUS is -$0.89 with a range of -$1.04 to -$0.77. The previous quarter’s EPS was -$0.72. RCUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 54.78% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.
Next quarter’s earnings estimate for RCUS is -$0.89 with a range of -$1.04 to -$0.77. The previous quarter’s EPS was -$0.72. RCUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 54.78% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.

RCUS Sales Forecast

Next quarter’s sales forecast for RCUS is $13.85M with a range of $0.00 to $45.00M. The previous quarter’s sales results were $41.00M. RCUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 67.08% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.
Next quarter’s sales forecast for RCUS is $13.85M with a range of $0.00 to $45.00M. The previous quarter’s sales results were $41.00M. RCUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 67.08% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.

RCUS Stock Forecast FAQ

What is RCUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcus Biosciences’s 12-month average price target is 38.44.
    What is RCUS’s upside potential, based on the analysts’ average price target?
    Arcus Biosciences has 35.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RCUS a Buy, Sell or Hold?
          Arcus Biosciences has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Arcus Biosciences’s price target?
            The average price target for Arcus Biosciences is 38.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $47.00 ,the lowest forecast is $23.00. The average price target represents 35.27% Increase from the current price of $28.42.
              What do analysts say about Arcus Biosciences?
              Arcus Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of RCUS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.